國家衛生研究院 NHRI:Item 3990099045/14270

NHRI > National Institute of Infectious Diseases and Vaccinology > Chia-Chyi Liu > Periodical Articles > Item 3990099045/14270

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14270

Title:	Intranasal immunization with zika virus envelope domain III-flagellin fusion protein elicits systemic and mucosal immune responses and protection against subcutaneous and intravaginal virus challenges
Authors:	Chen, CH;Chen, CC;Wang, WB;Lionel, V;Liu, CC;Huang, LM;Wu, SC
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	Zika virus (ZIKV) infections in humans are mainly transmitted by the mosquito vectors, but human-to-human sexual transmission is also another important route. Developing a ZIKV mucosal vaccine that can elicit both systemic and mucosal immune responses is of particular interest. In this study, we constructed a recombinant ZIKV envelope DIII (ZDIII) protein genetically fused with Salmonella typhimurium flagellin (FliC-ZDIII) as a novel mucosal antigen for intranasal immunization. The results indicated that the FliC-ZDIII fusion proteins formulated with E. coli heat-labile enterotoxin B subunit (LTIIb-B5) adjuvant greatly increased the ZDIII-specific IgG, IgA, and neutralizing titers in sera, and the ZDIII-specific IgA titers in bronchoalveolar lavage and vaginal fluids. Protective immunity was further assessed by subcutaneous and intravaginal ZIKV challenges. The secondgeneration FliC∆D3-2ZDIII was shown to result in a reduced titer of anti-FliC IgG antibodies in sera and still retained the same levels of serum IgG, IgA, and neutralizing antibodies and mucosal IgA antibodies without compromising the vaccine antigenicity. Therefore, intranasal immunization with FliC∆D3-2ZDIII fusion proteins formulated with LTIIb-B5 adjuvant elicited the greatest protective immunity against subcutaneous and intravaginal ZIKV challenges. Our findings indicated that the combination of FliC∆D3-2ZDIII fusion proteins and LTIIb-B5 adjuvant for intranasal immunization can be used for developing ZIKV mucosal vaccines.
Date:	2022-05-08
Relation:	Pharmaceutics. 2022 May 8;14(5):Article number 1014.
Link to:	http://dx.doi.org/10.3390/pharmaceutics14051014
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1999-4923&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000801733500001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85130236351
Appears in Collections:	[Chia-Chyi Liu] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85130236351.pdf		2230Kb	Adobe PDF	144	View/Open

Loading...